Chelly J E, Hill D C, Abernethy D R, Dlewati A, Doursout M F, Merin R G
Department of Anesthesiology, Baylor College of Medicine, Houston, Texas.
J Pharmacol Exp Ther. 1987 Oct;243(1):211-6.
Lidocaine (3 mg/kg i.v.) injected during steady-state verapamil infusions (3 micrograms/kg i.v.) induced slight and transient hemodynamic changes in nine conscious dogs. Systemic vascular resistance and left ventricular dP/dt decreased by 16% from 41 +/- 4 mm Hg/liter/min and by 20% from 2876 +/- 137 mm Hg/sec, respectively, whereas heart rate and cardiac output increased by 18% from 100 +/- 5 beats/min and by 17% from 2.5 +/- 0.2 liters/min, respectively. Simultaneously, lidocaine induced a transient but more pronounced decrease in verapamil plasma concentration of 48% from 60 +/- 3 ng/ml. This pharmacokinetic interaction was not the result of a lidocaine-induced decrease in the fraction of verapamil bound to plasma protein because in vitro lidocaine failed to displace verapamil from its protein binding site. Moreover, an increase in verapamil total clearance was not the only mechanism because steady-state lidocaine (6 mg/kg over 5 min followed by 60 micrograms/kg/min) in the presence of steady-state verapamil (200 micrograms/kg over 3 min followed by 3 micrograms/kg/min) also resulted in a transient decrease in verapamil plasma concentration from 59 +/- 9 to 23 +/- 2 ng/ml in six conscious dogs. Although verapamil did not affect lidocaine pharmacokinetics, in the presence of the steady-state lidocaine we recorded an increase in verapamil initial volume of distribution of 44% from 40 +/- 4 liters, and intercompartmental clearance increased by 88% from 101 +/- 20 liters/hr, combined with an increase in verapamil total clearance of 47% from 54 +/- 6 liters/hr (n = 6).
在对9只清醒犬进行稳态维拉帕米输注(静脉注射3微克/千克)期间,静脉注射利多卡因(3毫克/千克)引起了轻微且短暂的血流动力学变化。全身血管阻力和左心室dp/dt分别从41±4毫米汞柱/升/分钟下降了16%,从2876±137毫米汞柱/秒下降了20%,而心率和心输出量分别从100±5次/分钟增加了18%,从2.5±0.2升/分钟增加了17%。同时,利多卡因使维拉帕米血浆浓度从60±3纳克/毫升短暂但更显著地下降了48%。这种药代动力学相互作用并非利多卡因导致与血浆蛋白结合的维拉帕米比例降低的结果,因为在体外利多卡因未能将维拉帕米从其蛋白结合位点置换出来。此外,维拉帕米总清除率增加并非唯一机制,因为在稳态维拉帕米(3分钟内静脉注射200微克/千克,随后3微克/千克/分钟)存在的情况下,稳态利多卡因(5分钟内静脉注射6毫克/千克,随后60微克/千克/分钟)也导致6只清醒犬的维拉帕米血浆浓度从59±9纳克/毫升短暂下降至23±2纳克/毫升。尽管维拉帕米不影响利多卡因的药代动力学,但在稳态利多卡因存在的情况下,我们记录到维拉帕米的初始分布容积从40±4升增加了44%,室间清除率从101±20升/小时增加了88%,同时维拉帕米总清除率从54±6升/小时增加了47%(n = 6)。